Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease.
Post-surgical recurrence
Real-world
Rutgeerts
SN-IBD
Ustekinumab
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
revised:
05
04
2023
received:
16
01
2023
accepted:
20
04
2023
medline:
18
9
2023
pubmed:
6
5
2023
entrez:
6
5
2023
Statut:
ppublish
Résumé
Postoperative recurrence (POR) following ileocolonic resection is a major concern in patients with Crohn's disease (CD). The role of ustekinumab (UST) in this setting is poorly known. All consecutive CD patients with a baseline colonoscopy at 6-12 months from ileocolonic resection showing POR (Rutgeerts score ≥ i2) who were treated with UST after the baseline colonoscopy and with an available post-treatment endoscopy, were extracted from the cohort of the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). The primary outcome was endoscopic success, defined as reduction of at least one point of Rutgeerts score. The secondary outcome was clinical success, assessed at the end of follow-up. Reasons for clinical failure included mild clinical relapse (Harvey-Bradshaw index 5-7), clinically relevant relapse (Harvey-Bradshaw index > 7), and need for new resection. Forty-four patients were included (mean follow-up: 17.8 ± 8.4 months). The baseline postoperative colonoscopy showed severe POR (Rutgeerts score i3 or i4) in 75.0% of patients. The post-treatment colonoscopy was performed after a mean of 14.5 ± 5.5 months following initiation of UST. Endoscopic success was reported in 22 out of 44 (50.0%) patients, of whom 12 (27.3%) achieved a Rutgeerts score i0 or i1. Clinical success at the end of follow-up was reported in 32 out of 44 patients (72.7%); none of the 12 patients with clinical failure had achieved endoscopic success at post-treatment colonoscopy. Ustekinumab could be a promising option for the treatment of POR of CD.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Postoperative recurrence (POR) following ileocolonic resection is a major concern in patients with Crohn's disease (CD). The role of ustekinumab (UST) in this setting is poorly known.
METHODS
METHODS
All consecutive CD patients with a baseline colonoscopy at 6-12 months from ileocolonic resection showing POR (Rutgeerts score ≥ i2) who were treated with UST after the baseline colonoscopy and with an available post-treatment endoscopy, were extracted from the cohort of the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). The primary outcome was endoscopic success, defined as reduction of at least one point of Rutgeerts score. The secondary outcome was clinical success, assessed at the end of follow-up. Reasons for clinical failure included mild clinical relapse (Harvey-Bradshaw index 5-7), clinically relevant relapse (Harvey-Bradshaw index > 7), and need for new resection.
RESULTS
RESULTS
Forty-four patients were included (mean follow-up: 17.8 ± 8.4 months). The baseline postoperative colonoscopy showed severe POR (Rutgeerts score i3 or i4) in 75.0% of patients. The post-treatment colonoscopy was performed after a mean of 14.5 ± 5.5 months following initiation of UST. Endoscopic success was reported in 22 out of 44 (50.0%) patients, of whom 12 (27.3%) achieved a Rutgeerts score i0 or i1. Clinical success at the end of follow-up was reported in 32 out of 44 patients (72.7%); none of the 12 patients with clinical failure had achieved endoscopic success at post-treatment colonoscopy.
CONCLUSIONS
CONCLUSIONS
Ustekinumab could be a promising option for the treatment of POR of CD.
Substances chimiques
Ustekinumab
FU77B4U5Z0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1503-1509Informations de copyright
© 2023 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Abraham C, Cho JH. Inflammatory bowel disease. N. Engl. J. Med. 2009; 361: 2066-2078.
Pariente B, Cosnes J, Danese S et al. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm. Bowel Dis. 2011; 17: 1415-1422.
Vuitton L, Peyrin-Biroulet L. Pharmacological prevention of postoperative recurrence in Crohn's disease. Drugs 2020; 80: 385-399.
Frolkis AD, Lipton DS, Fiest KM et al. Cumulative incidence of second intestinal resection in Crohn's disease: a systematic review and meta-analysis of population-based studies. Am. J. Gastroenterol. 2014; 109: 1739-1748.
Bobanga ID, Bai S, Swanson MA et al. Factors influencing disease recurrence after ileocolic resection in adult and pediatric onset Crohn's disease. Am. J. Surg. 2014; 208: 591-596.
Buisson A, Chevaux J-B, Allen PB, Bommelaer G, Peyrin-Biroulet L. Review article: the natural history of postoperative Crohn's disease recurrence. Aliment. Pharmacol. Ther. 2012; 35: 625-633.
Orlando A, Mocciaro F, Renna S et al. Early post-operative endoscopic recurrence in Crohn's disease patients: data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort. J. Crohns Colitis 2014; 8: 1217-1221.
Adamina M, Bonovas S, Raine T et al. ECCO guidelines on therapeutics in Crohn's disease: surgical treatment. J. Crohns Colitis 2020; 14: 155-168.
Nguyen GC, Loftus EV Jr, Hirano I et al. American Gastroenterological Association Institute Guideline on the management of Crohn's disease after surgical resection. Gastroenterology 2017; 152: 271-275.
Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, Kerremans R. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108: 1617-1621.
Orlando A, Mocciaro F, Ventimiglia M et al. Azathioprine for prevention of clinical recurrence in Crohn's disease patients with severe endoscopic recurrence: an IG-IBD randomized double-blind trial. Eur. Rev. Med. Pharmacol. Sci. 2020; 24: 11356-11364.
Reinisch W, Angelberger S, Petritsch W et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 2010; 59: 752-759.
Yoshida K, Fukunaga K, Ikeuchi H et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. Inflamm. Bowel Dis. 2012; 18: 1617-1623.
Savarino E, Bodini G, Dulbecco P et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. Am. J. Gastroenterol. 2013; 108: 1731-1742.
Regueiro M, Schraut W, Baidoo L et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009; 136: 441-450.e1 quiz 716; quiz 716.
Papamichael K, Archavlis E, Lariou C, Mantzaris GJ. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study. J. Crohns Colitis 2012; 6: 924-931.
Regueiro M, Feagan BG, Zou B et al. Infliximab reduces endoscopic, but not clinical, recurrence of Crohn's disease after ileocolonic resection. Gastroenterology 2016; 150: 1568-1578.
De Cruz P, Kamm MA, Hamilton AL et al. Crohn's disease management after intestinal resection: a randomised trial. Lancet 2015; 385: 1406-1417.
López-Sanromán A, Vera-Mendoza I, Domènech E et al. on behalf of the Spanish GETECCU group [APPRECIA study]; Spanish GETECCU group [APPRECIA study]Adalimumab vs azathioprine in the prevention of postoperative crohn's disease recurrence. A GETECCU randomised trial. J. Crohns Colitis 2017; 11: 1293-1301.
Bonovas S, Piovani D, Pansieri C et al. Use of biologics for the management of Crohn's disease: IG-IBD technical review based on the GRADE methodology. Dig. Liver Dis. IN PRESS 2023.
Macaluso FS, Papi C, Orlando A et al. Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology. Dig. Liver Dis. IN PRESS 2023; 55: 442-453.
Mañosa M, Fernández-Clotet A, Nos P et al. Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: results from the ENEIDA registry. Dig. Liver Dis. 2023; 55: 46-52.
Toutouh SH, Sáez ML, Martínez ÁH. Ustekinumab for prevention of postoperative recurrence: our clinical experience. Gastroenterol. Hepatol. 2021; 44: 296-297.
Buisson A, Nancey S, Manlay L et al. Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease. United Eur. Gastroenterol. J. 2021; 9: 552-560.
Yanai H, Kagramanova A, Knyazev O et al. Endoscopic postoperative recurrence in Crohn's disease after curative ileocecal resection with early prophylaxis by anti-TNF, vedolizumab or ustekinumab: a real-world multicentre European study. J. Crohns Colitis 2022; 16: 1882-1892.
Axelrad JE, Li T, Bachour SP et al. Early initiation of antitumor necrosis factor therapy reduces postoperative recurrence of Crohn's disease following ileocecal resection. Inflamm. Bowel Dis. 2022: izac158.
Le Cosquer G, Altwegg R, Rivière P et al. Prevention of post-operative recurrence of Crohn's disease among patients with prior anti-TNFα failure: a retrospective multicenter study. Dig. Liver Dis. 2022: S1590-8658(22)00696-X.
Macaluso FS, Cappello M, Crispino F et al. Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's disease. Dig. Liver Dis. 2022; 54: 629-634.